Zuglimin 500mg Tablet contains Imeglimin, a novel oral antihyperglycemic agent indicated for the management of type 2 diabetes mellitus. Imeglimin acts by targeting mitochondrial bioenergetics, improving insulin sensitivity, and enhancing pancreatic beta-cell function, thereby contributing to improved glycemic control. Zuglimin is prescribed as part of a comprehensive diabetes management plan including diet, exercise, and other antidiabetic therapies when necessary. The recommended dosage is typically one 500mg tablet taken orally, with or without food, as directed by a healthcare professional. Clinical studies have demonstrated that Imeglimin effectively reduces fasting plasma glucose and HbA1c levels with a favorable safety profile. Common adverse effects may include mild gastrointestinal disturbances such as nausea or diarrhea, which are generally transient. Caution is advised in patients with renal impairment, and dosage adjustments may be required. Zuglimin should not be used in patients with type 1 diabetes or diabetic ketoacidosis. Regular monitoring of blood glucose levels and periodic assessment of renal function are recommended during therapy. Zuglimin 500mg Tablet offers a novel mechanism of action and represents an important therapeutic option for improving glycemic control in adults with type 2 diabetes mellitus.